Topics

Organoid-Based Drug Discovery: Generation And Applications

Tumor Microenvironment Cancer Immunotherapy Intercellular Communication & Diseases

Organoid-based drug discovery uses self-organizing three-dimensional cultures derived from stem cells, normal tissues, or patient tumors to model organ architecture, disease biology, and therapeutic response. The field began with intestinal stem-cell organoids, where single Lgr5-positive stem cells generated crypt-villus structures in vitro, and expanded into patient-derived tumor organoids that preserve histology, molecular features, and drug-response phenotypes of source cancers[1][2][3].

Generation usually starts from primary tissue or biopsy material, followed by embedding epithelial or tumor cells in extracellular matrix and culturing them with niche factors that sustain self-renewal, lineage identity, and three-dimensional growth. Organoid biobanks make this process scalable by collecting well-characterized living models from colorectal, breast, pancreatic, gastrointestinal, brain, and other tumors for genomic profiling, biomarker discovery, and high-throughput drug testing[2][4][5].

Applications now span target validation, compound screening, toxicity testing, resistance modeling, combination discovery, and functional precision medicine. Colorectal cancer organoid biobanks linked molecular profiles to drug sensitivity, metastatic gastrointestinal cancer organoids modeled patient treatment response, and breast cancer organoid biobanks captured disease heterogeneity for cancer research and drug development. Immune-organoid cocultures and organoid-on-chip systems extend the platform toward immunotherapy testing and tumor microenvironment modeling[2][3][4][6].

The major gaps are variable establishment rates, culture time, cost, stromal and immune-cell loss, matrix dependence, assay standardization, and incomplete representation of vascularization and systemic pharmacology. Future organoid-based drug discovery will require automated workflows, defined matrices, multi-omics integration, microfluidics, immune and stromal coculture, and prospective clinical trials that test whether organoid-guided therapy improves outcomes[3][6][7].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L049 Antibacterial Compound Library
Antibacterial agents are a group of materials that fight against pathogenic bacteria. Thus, by killing or reducing the metabolic activity of bacteria, their pathogenic effect in the biological environments will be minimized. The most widely used antibacterial agents exert their effects on bacterial cell wall synthesis, protein synthesis, DNA replication and metabolic pathways. However, resistance to antimicrobial agents has become a major source of morbidity and mortality worldwide. The main mechanisms of resistance are limiting uptake of a drug, modification of a drug target, inactivation of a drug, and active efflux of a drug. Therefore, it is an urgent need to develop new drugs targeted at resistant organisms. MCE offers a unique collection of 1,994 compounds with validated antibacterial activities. MCE antibacterial compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

Disease Focused Libraries

92
HY-L052 Anti-COVID-19 Compound Library
COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs. Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1,380 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.

Disease Focused Libraries

90
HY-L122 FDA-Approved Anticancer Drug Library
Cancer is the second leading cause of death worldwide and a serious threat to human health. Multiple treatments have been developed for cancer treatment, but new anti-cancer drugs still need to be developed urgently. Approved drugs, have well-characterized bioactivities, safety and bioavailability properties, will dramatically accelerate drug development. MCE offers a unique collection of 1,540 approved drugs with anti-cancer activity, which can be used for discovery of new anti-cancer drugs or as positive compounds used for anti-cancer research.

Disease Focused Libraries Drug Repurposing Series

89
HY-L109 Protein-protein Interaction Inhibitor Library
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 826 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Signaling Pathway Targeting Libraries

86
HY-L904 Drug Fragment Library
The MCE 1K Drug Fragment Library consists of 1,394 drug fragments. These drug fragments are derived from 2,946 FDA-approved drug molecules, and fragments from one drug can appear in other drugs, so these fragments are somewhat correlated with good PK/PD properties. Fragment-based screening can reserve enough chemical space for subsequent structural optimization. This compound library is an essential tool for drug screening based on FBDD (Fragment-Based Drug Discovery).

Featured Fragment Libraries

85
HY-L053 NMPA-Approved Drug Library
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc. MCE provides a unique collection of 1,534 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

84
HY-L115 Plant-Sourced Natural Product Library
Natural products are characterized by enormous scaffold diversity and structural complexity, because of which, natural products do show a wide range of biological activities. Medicinal plants have been the major source of medicines over many centuries. About a quarter of all Food and Drug Administration (FDA) and/or the European Medical Agency (EMA) approved drugs are plant based, with well-known drugs such as Paclitaxel and Aspirin having been isolated from plants. MCE provides a unique collection of 3,352 plant-sourced natural products. MCE Plant-Sourced Natural Product Library is a useful tool for drug discovery that can be used for high throughput screening (HTS) and high content screening (HCS).

Natural Product Screening Libraries

84
HY-L116 EMA-Approved Drug Library
MCE EMA-Approved Drug Library consists of 728 EMA-approved drugs with high pharmacological diversity. All drugs in this library have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE EMA-Approved Drug Library is a useful tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

84
HY-L001V MCE Bioactive Compound Library
A unique collection of 34,325 bioactive compounds including natural products, enzyme inhibitors, receptor ligands, and drugs for high throughput screening (HTS) and high content screening (HCS).
83
HY-L0093V Chemspace Scaffold derived set
Diversity-based screening continues to be a vital tool for drug discovery. Efficiency and productivity can be improved by using screening libraries that offer maximum diversity whilst retaining drug-like properties. Chemspace Scaffold derived set composes 10,119 compounds, which including 3,373 scaffolds, 3 compounds per each. This library has exceptional coverage of drug-like chemical space.
83
HY-L0113V 1M Drug Fragment-Based Diversity Library
A diversity compound library contains 1,000,000 compounds with drug fragments. Each compound has at least one drug fragment. These selected molecules have 702,902 Bemis-Murcko Scaffolds (BMS) with drug-like chemical space. This library is highly recommended for AI-based lead discovery, ultra-large virtual screening and novel lead discovery.
83
HY-L021M Natural Product and Natural Product-Like Compound Library
From the discovery of traditional Chinese medicine to modern antibiotics, natural products have played an important role in the drug development process. A review of all FDA-approved drugs shows that natural products and natural product-like compounds account for more than one-third of all approved drugs. Nearly half of that came from mammals, a quarter from microbes, and a quarter from plants. Over time, the proportion of microbial natural products and natural product derivatives in approved drugs has increased. Natural products have natural advantages in drug development and can be used as lead compounds in drug discovery for drug identification and mechanism research. MCE provides a unique collection of 20,566 natural compounds and natural product-like compounds that contain saccharides and glycosides, phenylpropanoids, quinones, flavonoids, terpenoids and glycosides, steroids, alkaloid, phenols, acids and aldehydes. Natural product and natural product-like compounds library is a useful tool for drug discovery that can be used for high-throughput screening (HTS) and high-content screening (HCS).
83
HY-L098 Drug Metabolite Library
A drug metabolite is a byproduct of the body breaking down, or “metabolizing” a drug into a different substance. Most drugs undergo chemical alteration by various bodily systems as a way to create compounds that are more easily excreted from the body. Drugs can be metabolized by oxidation, reduction, hydrolysis, hydration, conjugation, condensation, or isomerization. Drug metabolism can produce metabolites with physicochemical and pharmacological properties that differ substantially from those of the parent drug, and consequently have important implications for both drug safety and efficacy. MCE offers a unique collection of 440 drug metabolites which is a useful tool for drug safety and efficacy study and drug repurposing.

Compound Characteristic Classified Libraries

83
HY-L200 RO5 Drug-like Natural Product Library
Natural products are small molecular compounds that occur in nature and come from any organism, including primary and secondary metabolites. Natural products have potential biological activity and can be used as lead compounds for drug discovery. Nature has been a source of medicines for thousands of years, and a large number of drugs have been isolated from nature, many based on their use in traditional medicine. With the development of compound targets, there is an increasing need to screen for compound diversity. Through ongoing research into natural biodiversity, much of which remains to be exploited, natural products will play a key role in meeting this demand. The Lipinski rule of 5 is used to describe the drug-like properties of a molecule, molecules that adhere to the rule of 5 have higher drug potential. Based on MCE natural product library, MCE selects the molecules that obey the rule of 5, which makes the efficiency of drug screening higher. MCE designs a unique collection of 2,818 RO5 drug-like natural products, which is an important tool for drug discovery.
83
HY-L216 Polysaccharides Compound Library
Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development. MCE offers 70 polysaccharides that can be used in biomedical studies.
83
HY-L218 Animal Drug Library
Animal drug (also veterinary drug) refers to a drug intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. Animal Drugs @ FDA is a searchable online database that includes most FDA-approved and conditionally approved animal drugs. The major classes of veterinary drugs include antibiotics, anthelmintics, coccidiostats, nonsteroidal anti-inflammatory drugs, sedatives, corticosteroids, beta-agonists, and anabolic hormones. MCE has collected 166 FDA-approved veterinary drug compounds for use in scientific research.
83
HY-L906 Norepinephrine Transporter (NET) Compound Library
On May 15, 2024, "Dimerization and antidepressant recognition at noradrenaline transporter" was published online by Nature. The research findings were an effort from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This study unraveled the important neural system target - the noradrenaline transporter (NET), obtaining the binding modes of human NET homodimers with the natural substrate norepinephrine (NE) and six selective antidepressants. It laid an important theoretical foundation for understanding the physiological regulation mechanisms of NET and other monoamine transporters. The Norepinephrine Transporter (NET) Compound Library is obtained by computer-aided virtual screening based on the HY-L901 compound library . The specific screening process includes molecular docking screening, key pharmacophore screening, and CNS-MPO screening, which can be used for new drug discovery targeting the noradrenaline transporter.

Focused and target libraries

83
HY-L938 Antifungal Lead-like compound library
Currently,the incidence and mortality rates of clinical fungal infections remain high. Existing antifungal drugs are limited in variety and associated with numerous adverse effects, creating an urgent demand for the development of novel antifungal agents. Antifungal compound libraries can support the screening and development of new antifungal drugs. The mechanisms of action of antifungal drugs cover key processes such as fungal cell membrane synthesis, cell wall synthesis, and cell division. They exert fungicidal or fungistatic effects by specifically targeting different molecular pathways. This library includes a variety of core analogs of antifungal drugs, making it adaptable to antifungal research in diverse scenarios. It can be used for the high-throughput screening of novel antifungal drug candidates, enabling the rapid identification of compounds with potential antifungal activity and facilitating the elucidation of drug-target interactions and resistance mechanisms. Additionally, it supports the screening of compounds and combinations that reverse drug resistance, thereby uncovering the novel antifungal potential of existing compounds. The library comprises 8350 compounds with a well-defined screening strategy. The core sources of the compounds include analogs of known antifungal active moleculeswith a similarity score of ≥ 0.6 MCE has collected more than 500 antifungal molecules.All screened compounds conform to lead-like physicochemical properties, exhibiting both structural diversity and drug-like characteristics, and providing valuable support for the research and development of novel antifungal drugs.

Focused and target libraries

83
HY-L943 MCE‑18 Novelty drug‑like Library
MCE-18 stands for Medicinal Chemistry Evolution 2018, which was first published in Journal of Medicinal Chemistry in 2019 for assessing molecular novelty and three-dimensional complexity. Developed based on Clarivate global pharmaceutical patent database, this descriptor was constructed via big-data analysis covering 28,161 patented lead compounds, 1,370 approved drugs and nearly 30,000 preclinical-to-phase III drug candidates from 23 top pharmaceutical companies worldwide between 1950 and 2018, followed by structural clustering and removal of redundant outdated scaffolds for data denoising. Its scoring system integrates five core structural features including aromatic ring (AR), aliphatic heterocycle (NAR), chiral center (CHIRAL), spiro atom (SPIRO), cyclic and acyclic sp³ carbon ratio together with a quadratic topological correction factor. Breaking the limitations of the single Fsp³ parameter, MCE-18 effectively distinguishes conventional flat aromatic scaffolds from modern 3D-enriched novel chemotypes, overcoming typical drawbacks of traditional compound libraries such as scaffold redundancy, low screening hit rates and poor compatibility with allosteric and PPI-related difficult targets. This library contains over 37,000 structurally diverse compounds with favorable overall drug-likeness, suitable for high-throughput screening against canonical targets including kinases, GPCRs and proteases as well as challenging allosteric and PPI targets. Compounds comply with the developmental trend of modern novel drug discovery, supporting routine primary screening as well as early hit identification of allosteric modulators and PPI inhibitors, serving as an efficient screening resource for early-stage innovative drug discovery.

Distinctive Diversity Libraries

83
HY-L944 MCE‑18 Novelty Focused Drug‑Like Library
MCE 18 stands for Medicinal Chemistry Evolution 2018. This metric was established based on structural data of 28,161 patented lead molecules, 1,370 marketed innovative drugs, and nearly 30,000 investigational candidates from preclinical to Phase III stages across 23 major global pharmaceutical companies from 1950 to 2018. After scaffold clustering analysis, a scoring model was constructed by integrating five three dimensional scaffold characteristics, including aromatic rings (AR), non aromatic heterocycles (NAR), chiral centers (CHIRAL), spirocycles (SPIRO), and the sp³ carbon ratio in cyclic and acyclic moieties, enabling quantitative assessment of molecular scaffold novelty and three dimensional complexity. According to the score distribution of patented molecules, the top 25% of the original patent dataset was defined as the high novelty region. MCE 18 high scoring compounds selected based on this criterion can effectively avoid scaffold patent conflicts and intellectual property risks from the source. Molecules in this range typically feature a high sp³ carbon ratio, abundant chiral centers, spirocycles, and fused heterocycles with prominent three dimensional conformations. Their spatial properties allow precise matching to complex non traditional undruggable target pockets such as PPI interfaces and allosteric sites, making them ideal structural types for early stage screening of First in class drugs. MCE‑18 Novelty Focused drug‑Like library strictly selects molecules from the aforementioned high scoring range, containing more than 10,000 premium drug like molecules with highly diverse scaffolds and rich 3D diversity. It can be used for high throughput screening of well established targets such as kinases, GPCRs, and proteases, and is especially suitable for hit identification in allosteric modulation, protein–protein interactions, and various undruggable orphan targets, fully supporting early stage drug discovery for cutting edge innovat

Distinctive Diversity Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-K6002 Basement Membrane Matrix

MCE Basement Membrane Matrix is primarily composed of natural basement membrane matrix extracted from mouse tumors.This product is mainly used for studies of tumor invasion, angiogenesis and organoids culture while avoiding color interference in subsequent experiments.

Cell Biology 3D Cell Culture Basement Membrane Matrix

25
HY-N7131 Coumarin 6
Coumarin 6, a fluorescent dye, is used as a fluorescent probe in a microparticle drug delivery system to conduct in vivo tracking, cell uptake, and transport mechanism studies of drug delivery systems (λexc=450 nm, λem=505 nm).
Fluorescent Dye  
24
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-K6001 Basement Membrane Matrix (Phenol Red)

MCE Basement Membrane Matrix (Phenol Red) is primarily composed of a natural basement membrane matrix derived from mouse tumors. This product is mainly for studies of tumor invasion, angiogenesis, and organoid culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

21
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-N0527 Pentagalloylglucose
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities.
JAK   Keap1-Nrf2   Apoptosis   β-catenin   Reactive Oxygen Species (ROS)   E1/E2/E3 Enzyme  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
16
HY-D0040 Calcein
Calcein is a fluorescent dye and self-quenching probe, used as an indicator of lipid vesicle leakage, and also as a complexometric indicator for titration of calcium ions with EDTA, and for fluorometric determination of calcium. Calcein cannot directly cross the intact cell membrane of a living cell, unlike Calcein-AM (HY-D0041) which is cell-permeable. Calcein can also be used as a model drug for evaluating efficiency and bioavailability of drug delivery systems.
Fluorescent Dye  
15
HY-P99045A Sacituzumab (powder)
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.

Species: Human

ADC Antibodies   TROP2  
Cancer  
9
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-P1454A Fz7-21 TFA
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids.
Wnt  
Cancer  
3
HY-P1454 Fz7-21
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids.
Wnt  
Cancer  
3
HY-W010991 N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly
N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly (FAPGG) is a specific substrate of angiotensin converting enzyme (ACE) with a Ki of 2.546×10-4 M. It is used as a chromogenic probe for quantitative detection of ACE activity. N-[3-(2-Furyl)acryloyl]-Phe-Gly-Gly can be hydrolyzed by ACE to generate N-[3-(2-furyl)acryloyl]-Phe (FAP) and Gly-Gly, and the ACE inhibitory effect is monitored by photometry. FAPGG competitively binds to the active center of ACE and is a key tool for screening ACE inhibitors such as Captopril (HY-B0368) and Dioscorin. Its reversible mechanism of action supports hypertension research and drug development targeting the renin-angiotensin system.
Angiotensin-converting Enzyme (ACE)  
3
HY-N0402 Artemether
Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria.
Parasite  
Cancer   Inflammation or Immune System Disease   Parasitic Infection  
3
HY-P80842 Phospho-p38 alpha/MAPK14 (Thr180/Tyr182) Antibody
Phospho-p38 alpha/MAPK14 (Thr180/Tyr182) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-p38 alpha/MAPK14 (Thr180/Tyr182).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Modification Specific Antibodies Primary Antibodies

3
HY-K1099 Endotoxin Detection Kit (Recombinant Factor C)

MCE Endotoxin Detection Kit (Recombinant Factor C) is suitable for the detection of endotoxins in therapeutic injectable drugs for human use (such as chemical drugs, antibiotics, and biologics), as well as in medical devices including dialysis fluids and implantable devices. It can be applied throughout raw material screening, process development, manufacturing, and commercialization stages.

Cell Biology Cell Analysis Endotoxin Detection

3
HY-W012860 p-Tolualdehyde
p-Tolualdehyde is the active small molecule, that could used as drug intermediate.
Environmental Pollutants   Drug Intermediate  
2
HY-P990173 Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer.

Species: Human/Mouse/Rat

PD-1/PD-L1  
Cancer  
2
HY-W019823 4-MUNANA
4-MUNANA is a substrate of influenza virus neuraminidase (NA) with high selectivity and irreversible reaction. In the enzymatic reaction, 4-MUNANA is hydrolyzed by NA to generate fluorescent 4-methylumbelliferone (4-MU). By detecting the fluorescence intensity of 4-MU, quantitative analysis of NA activity can be achieved. 4-MUNANA can be used in influenza-related research, such as screening NA inhibitors, developing new anti-influenza drugs, and studying the infection mechanism of influenza viruses.
Fluorescent Dye  
Infection   Neurological, Eye or Ear Disease  
2
HY-P80996 p38 alpha/MAPK14 Antibody (YA3534)
p38 alpha/MAPK14 Antibody (YA3534) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 alpha/MAPK14.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

2
HY-P80777 p38 alpha/MAPK14 Antibody (YA252)
p38 alpha/MAPK14 Antibody (YA252) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 alpha/MAPK14.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

2
HY-P80776 p38 alpha/MAPK14 Antibody (YA696)
p38 alpha/MAPK14 Antibody (YA696) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p38 alpha/MAPK14.

Host: Mouse; Reactivity: Human, Mouse, Rat, Monkey

Monoclonal Antibodies Primary Antibodies

2
HY-K6004 Basement Membrane Matrix GFR

MCE Growth Factor Reduced Basement Membrane Matrix (Phenol Red-Free) is primarily composed of natural basement membrane matrix extracted from mouse tumors and contains abundant extracellular matrix components and a variety of naturally occurring growth factors. This product is primarily designed for 3D organoid culture and other research applications requiring high-quality basement membrane matrix. The phenol red-free formulation avoids potential interference with experiments requiring subsequent colorimetric or color-based analysis.

Cell Biology 3D Cell Culture Basement Membrane Matrix

2
HY-K6007 Basement Membrane Matrix for Organoid Culture

MCE Basement Membrane Matrix for Organoid Culture is primarily composed of natural basement membrane matrix extracted from mouse tumors. This product is mainly used for organoid culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

2
HY-K6011 Tumor Tissue Dissociation Solution

MCE Tumor Tissue Dissociation Solution is able to gently and efficiently dissociate tumor tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids.

Cell Biology 3D Cell Culture Organoid Research

2
HY-P99854A Disitamab (powder)
Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985).

Species: Human

EGFR   ADC Antibodies  
Cancer  
1
HY-P10128 GE11
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
1
HY-P2529 Penetratin
Penetratin is a cell-penetrating peptides derived from a nonviral protein. Penetratin can powerfully enhance drug absorption. Penetratin can be used for drug delivery research in the treatment of various diseases.
Others  
1
HY-P99854 Disitamab
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985).

Species: Human

EGFR   ADC Antibodies  
Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P73335 p38 alpha/MAPK14 Protein, Human (Active, sf9, His)
The p38 α/MAPK14 protein is an important serine/threonine kinase in the MAP kinase pathway. It can respond to stimuli such as cytokines or stress and directly activate transcription factors. In this cascade, p38 MAPK each phosphorylates approximately 200 to 300 substrates, including the downstream kinases RPS6KA5/MSK1 and RPS6KA4/MSK2, which are critical for immediate early gene induction. p38 alpha/MAPK14 Protein, Human (Activated, sf9, His) is the recombinant human-derived p38 alpha/MAPK14 protein, expressed by Sf9 insect cells , with N-His labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC MAPK Family MAPK Mitogen-Activated Protein Kinase 14 (p38 alpha/MAPK14)

1
HY-P80213 p38 alpha/MAPK14 Antibody (YA706)
p38 alpha/MAPK14 Antibody (YA706) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to p38 alpha/MAPK14.

Host: Mouse; Reactivity: Human, Mouse

Monoclonal Antibodies Primary Antibodies

1
HY-K6105 Human Gastric Cancer Organoid Kit

MCE Human Gastric Cancer Organoid Kit contains Gastric Cancer Organoid Basal Medium A, Gastric Cancer Organoid Supplement B (50×), Gastric Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human gastric cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

1
HY-166975 Polysarcosine 100
Polysarcosine 100 (pSar 100) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 100 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-N7018 20-Hydroxyganoderic Acid G
20-Hydroxyganoderic Acid G is a lanostane triterpenoid obtained from the EtOH extract of fruiting bodies of the Ganoderma curtisii. 20-Hydroxyganoderic Acid G inhibits BV-2 microglia cells activated by LPS with an IC50 of 21.33 μM. 20-Hydroxyganoderic Acid G has therapeutic potential in the agent discovery of nerve inflammation diseases associated with microglia activated by LPS.
Others  
Inflammation or Immune System Disease  
/
HY-W440932 Stearic acid-mPEG5000
Stearic acid-mPEG5000 is a PEG lipid that can improve the delivery efficiency and tissue specificity of poorly soluble drugs. Stearic acid-mPEG5000 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-128753S3 D-Lyxose-13C-2
D-Lyxose-13C-2 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
Isotope-Labeled Compounds   Endogenous Metabolite   Drug Intermediate  
/
HY-W440930 Stearic acid-mPEG1000
Stearic acid-mPEG1000 is a PEG lipid that can improve the delivery efficiency and tissue specificity of poorly soluble drugs. Stearic acid-mPEG1000 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-128753S6 D-Lyxose-d
D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
Isotope-Labeled Compounds   Endogenous Metabolite   Drug Intermediate  
Metabolic or Endocrine Disease  
/
HY-109541S3 Colfosceril miristate-d13
Colfosceril miristate-d13 (DMPC-d13) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
Isotope-Labeled Compounds  
/
HY-W440942 Pentacosadiynoic acid-mPEG2000
Pentacosadiynoic acid-mPEG2000 is a PEG lipid that can improve the delivery efficiency and tissue specificity of poorly soluble drugs. Pentacosadiynoic acid-mPEG2000 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-109541S Colfosceril miristate-d58
Colfosceril miristate-d58 (DMPC-d58) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
Isotope-Labeled Compounds  
Cancer  
/
HY-P991668 PF-06688992 Antibody
PF-06688992 Antibody is an antibody targeting GD3. PF-06688992 Antibody can be used for the synthesis of the antibody-drug conjugate PF-06688992 (HY-P991668).

Species: Human

ADC Antibodies  
Cancer  
/
HY-P992340 CTB006
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   TNF Receptor  
Colorectal Cancer  
/
HY-P11886 GNYTCEVTELTREGETIIELK-N3
GNYTCEVTELTREGETIIELK-N3 (GNYTCEVTELTREGETIIELK-Azide) is a conjugate of an azide (-N3) group and a CD47 functional peptide (GNYTCEVTELTREGETIIELK). Modifying the surface of LNPs with GNYTCEVTELTREGETIIELK significantly reduces the recognition and clearance of LNPs by the mononuclear phagocytic system (MPS) and reduces their accumulation in non-target tissues such as the liver and spleen. The azide group in GNYTCEVTELTREGETIIELK-N3 can undergo click chemistry reactions for applications such as constructing targeted drug delivery systems and nanoparticle modification.
Biochemical Assay Reagents  
/
HY-W414069 Thiocholesterol
Thiocholesterol is a member of the class of cholesteric liquid crystals (CLCs) that can be used to synthesis cationic lipid. Thiocholesterol is a stronger stabilizer of silver nanoparticles (SNPs). Thiocholesterol can be used for plasma membrane research and drug delivery.
Endogenous Metabolite   Liposome  
/
HY-128753S7 D-Lyxose-d-1
D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
Isotope-Labeled Compounds   Endogenous Metabolite   Drug Intermediate  
Metabolic or Endocrine Disease  
/
HY-P10989 NG2 binding peptide
NG2 binding peptide is a short peptide that specifically recognizes NG2 proteoglycan and can be obtained by phage screening technology. NG2 binding peptide interacts with NG2 binding sites to achieve precise targeting of tumor angiogenesis in vitro and in vivo. NG2 binding peptide exhibits significant homing ability in wild-type tumor-bearing mice, but has no localization effect in NG2 knockout mice. Due to the tissue specificity of NG2 expression, NG2 binding peptide can be used in scenarios such as tumor targeted therapy, drug delivery, and molecular imaging diagnosis.
Others  
Cancer  
/
HY-166973 Polysarcosine 20
Polysarcosine 20 (pSar 20) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 20 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-109541S1 Colfosceril miristate-d4
Colfosceril miristate-d4 (DMPC-d4) is deuterium labeled Colfosceril miristate. Colfosceril miristate is a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
Isotope-Labeled Compounds  
Cancer  
/
HY-128753R D-Lyxose (Standard)
D-Lyxose (Standard) is the analytical standard of D-Lyxose. This product is intended for research and analytical applications. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
Reference Standards   Endogenous Metabolite   Drug Intermediate  
Metabolic or Endocrine Disease  
/
HY-D3224 HCP
HCP is a two-photon fluorescent probe capable of crossing the blood-brain barrier, which is specifically designed for real-time detection of hypochlorous acid (HClO/ClO-) produced by myeloperoxidase (MPO). Chlorination of the quinoline skeleton of HCP generates HCP-Cl, which eliminates intramolecular charge transfer (ICT) quenching and thereby produces fluorescence. HCP is suitable for in vivo dynamic imaging of HClO in the brains of epileptic mice and high-throughput screening of antiepileptic drugs (HCP-Cl: Ex/Em = 800 nm/495 nm).
Fluorescent Dye  
Epilepsy  
/
HY-109541S4 Colfosceril miristate-d63
Colfosceril miristate-d63 (DMPC-d63) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
Isotope-Labeled Compounds  
Cancer  
/
HY-143211 Murapalmitine
Murapalmitine is the component of liposomes for drug delivery.
Liposome  
/
HY-P6299 MAX8
MAX8 is a synthetic β-hairpin peptide that folds rapidly and self-assembles into a β-sheet-rich fibrous hydrogel network via non-covalent crosslinking. MAX8 hydrogel exhibits excellent shear-thinning and self-healing properties, enabling precise delivery via syringe and maintaining local retention after implantation. MAX8 hydrogel can uniformly encapsulate cells while preserving their viability and morphology, and protect growth factors (e.g., NGF) and chemotherapeutic drugs from degradation. MAX8 is applicable for spinal cord injury repair, medulloblastoma treatment, and three-dimensional high-throughput drug screening.
Biochemical Assay Reagents  
Nervous System Injury   Glioblastoma  
/
HY-W440941 Pentacosadiynoic acid-mPEG1000
Pentacosadiynoic acid-mPEG1000 is a PEG lipid that can improve the delivery efficiency and tissue specificity of poorly soluble drugs. Pentacosadiynoic acid-mPEG1000 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-P10220 NOTA-COG1410
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with 68Gallium (68Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
Radionuclide-Drug Conjugates (RDCs)   TREM receptor  
/
HY-128753S4 D-Lyxose-13C-3
D-Lyxose-13C-3 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose.
Isotope-Labeled Compounds   Endogenous Metabolite   Drug Intermediate  
/
HY-N144101 SARS-CoV MPro-IN-2
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 72.07 nM. The main protease (Mpro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19.
SARS-CoV  
/
HY-N8858 5-Methyl-3-heptanone
5-Methyl-3-heptanone is an intermediate for drug synthesis.

Source: Streptomyces cinnamomeus-like

Others  
/
HY-166974 Polysarcosine 150
Polysarcosine 150 (pSar 150) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 150 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-N3855 Erythrabyssin II
Erythrabyssin II (EL-19) is a potent late-stage autophagy inhibitor that blocks the fusion of autophagosome and lysosome. Erythrabyssin II leads to the accumulation of autophagic substrates and does not impair lysosomal pH or lysosomal enzyme activity. Erythrabyssin II suppresses ovarian cancer organoid activity and induces apoptosis. Erythrabyssin II can be used for the study of ovarian cancer.
Autophagy   Apoptosis  
/
HY-N7131R Coumarin 6 (Standard)
Coumarin 6 (Standard) is the analytical standard of Coumarin 6 (HY-N7131). This product is intended for research and analytical applications. Coumarin 6, a fluorescent dye, is used as a fluorescent probe in a microparticle drug delivery system to conduct in vivo tracking, cell uptake, and transport mechanism studies of drug delivery systems (λexc=450 nm, λem=505 nm).
Fluorescent Dye   Reference Standards  
/
HY-D2921 BODIPY-FL-Vindoline
BODIPY-FL-Vindoline is a high-affinity fluorescent probe for the pregnane X receptor (PXR), with a Kd of 256 nM. BODIPY-FL-Vindoline can be used in the research of drug metabolism and drug-drug interactions.
Others  
/
HY-113945 Abbeymycin
Abbeymycin is an antibiotic derived from the actinobacterium Streptomyces sp. AB-999F-52. Abbeymycin is a specifically acting antibiotic with antimicrobial activity, primarily targeting anaerobic bacteria. Abbeymycin is employed in research concerning antibiotic discovery and screening.

Source: Streptomyces sp.

Antibiotic   Bacterial  
Infection  
/
HY-D2431 Galactose-PEG-Cy3
Galactose-PEG-Cy3 is a Cy3 (HY-D0822) labeled Galactose-PEG conjugate. The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. Galactose-PEG improves drug cellular uptake and reduces endosomal degradation, and can be used in drug delivery.
Fluorescent Dye  
/
HY-P9994 Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research.
Antibody-Drug Conjugates (ADCs)   EGFR   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-78921AG Fmoc-3VVD-OH (GMP)
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-P10699 MAX1
MAX1 is a synthetic β-hairpin peptide that folds rapidly and self-assembles into a β-sheet-rich fibrous hydrogel network via non-covalent crosslinking. MAX1 hydrogel exhibits excellent shear-thinning and self-healing properties, enabling precise delivery via syringe and maintaining local retention after implantation. MAX1 hydrogel can uniformly encapsulate cells while preserving their viability and morphology, and protect growth factors (e.g., NGF) and chemotherapeutic drugs from degradation. MAX1 is applicable for spinal cord injury repair, medulloblastoma treatment, and three-dimensional high-throughput drug screening.
Biochemical Assay Reagents  
Nervous System Injury   Glioblastoma  
/
HY-P11603 SK56
SK56 is a GSDMD-NT pore inhibitor. SK56 inhibits pyroptosis (Pyroptosis) and the release of pyroptosis-related cytokines in macrophages and human peripheral blood leukocytes. SK56 prevents extensive cell death in human alveolar organoids in an organoid-macrophage co-culture model. SK56 prevents death from infectious shock induced by LPS (HY-D1056) or cecal ligation and puncture in mice. SK56 can be used in studies related to sepsis.
Pyroptosis  
Inflammation or Immune System Disease  
/
HY-P4117 Penetratin-Arg
Penetratin-Arg is an antimicrobial and is used for drug delivery vehicle.
Bacterial  
Inflammation or Immune System Disease  
/
HY-109541S2 Colfosceril miristate-d9
Colfosceril miristate-d9 (DMPC-d9) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
Isotope-Labeled Compounds  
Cancer  
/
HY-P5304A RTQLLWTPAAPTAMA TFA
RTQLLWTPAAPTAMA TFA is a peptide antigen，used for drug delivery in immune response.
Others  
Inflammation or Immune System Disease  
/
HY-DY1034 4-MUNANA (solution)
4-MUNANA (solution) is a substrate of influenza virus neuraminidase (NA) with high selectivity and irreversible reaction. In the enzymatic reaction, 4-MUNANA is hydrolyzed by NA to generate fluorescent 4-methylumbelliferone (4-MU). By detecting the fluorescence intensity of 4-MU, quantitative analysis of NA activity can be achieved. 4-MUNANA can be used in influenza-related research, such as screening NA inhibitors, developing new anti-influenza drugs, and studying the infection mechanism of influenza viruses.
Solvent and Concentration: Sterile water: 10 mM
Fluorescent Dye  
/
HY-D2433 Glucose-PEG2000-Cy3
Glucose-PEG2000-Cy3 is a Cy3 (HY-D0822) labeled Glucose-PEG conjugate. The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. Glucose-PEG improves drug cellular uptake and reduces endosomal degradation, and can be used in drug delivery.
Fluorescent Dye  
/
HY-P10895 HR97 TFA
HR97 TFA is a cell-penetrating peptide that can be combined with engineered melanin to prepare eye drops HR97-SunitiGel. The peptide-drug conjugate in HR97-SunitiGel can provide sustained ocular drug delivery.
Biochemical Assay Reagents  
/
HY-N0527R Pentagalloylglucose (Standard)
Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities.
Reference Standards   JAK   Keap1-Nrf2   Apoptosis   β-catenin   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-D2841 FITC-Heparin
FITC-Heparin is a fluorescent dye composed of FITC (HY-66019) and Heparin. FITC-Heparin can be used for cell tracing and drug delivery.
Fluorescent Dye  
/
HY-B0803S1 Lumefantrine-d9
Lumefantrine-d9 is the deuterium labeled Lumefantrine. Lumefantrine is an antimalarial drug, used in combination with Artemether. The artemether-lumefantrine (AL) as the first- and second-line anti-malarial drugs.
Isotope-Labeled Compounds   Parasite   Autophagy  
Infection  
/
HY-D2415 BODIPY-FL staurosporine
BODIPY-FL staurosporine (Compound 8a) is a fluorescence probe based on staurosporine, exhibiting high specificity towards tyrosine kinases (TK) and tyrosine kinase-like (TKL) family kinases. BODIPY-FL staurosporine has the potential to develop binding assays for kinases that are not recommended for use with Kinase Tracer 236, such as PIM3, CDC42BPG, MAP2K7, TXK, and SIK3. BODIPY-FL staurosporine can be a powerful tool for analyzing kinase selectivity in kinase drug discovery.
Fluorescent Dye  
/
HY-P99238 Rolinsatamab
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C).

Species: Human

ADC Antibodies  
Cancer   Inflammation or Immune System Disease  
/
HY-N8275 (R)-(+)-Citronellic acid
(R)-(+)-Citronellic acid is a chiral carboxylic acid and can be used as a drug intermediate.

Source: Streptomyces sp.

Drug Intermediate  
/
HY-N12931F Maackia amurensis Lectin (MAA/MAL II)-Biotinylated
Maackia amurensis Lectin (MAA/MAL II)-Biotinylated is a plant lectin modified by biotin. Maackia amurensis Lectin (MAA/MAL II)-Biotinylated has the activity to recognize specific sugar structures, specifically the alpha-2, 3-linked sialic acid (HY-I0400). Maackia amurensis Lectin (MAA/MAL II)-Biotinylated has a very high affinity with avidin or streptavidin and this interaction can be used to fix it to solid surfaces or bind it to other molecules. Maackia amurensis Lectin (MAA/MAL II)-Biotinylated can be used to isolate and purify proteins or other molecules with specific sugar chain structures in affinity chromatography as well as for disease marker discovery and cancer research.
Fluorescent Dye  
/
HY-166979 Stearic acid-mPEG2000
Stearic acid-mPEG2000 is a PEG lipid that can improve the delivery efficiency and tissue specificity of poorly soluble drugs. Stearic acid-mPEG2000 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-P99007 Aprutumab
Aprutumab (BAY 1179470) is a fully human fibroblast growth factor receptor 2 (FGFR2)-specific monoclonal antibody. Aprutumab induces FGFR2 endocytosis and degradation in cancer cells expressing FGFR2. Aprutumab serves as the targeted monoclonal antibody component of the antibody-drug conjugate BAY 1187982 (HY-141600) and mediates the endocytosis of the antibody-drug conjugate into FGFR2-positive cells. Aprutumab can be used for the research of FGFR2-positive solid tumors, including studies on gastric cancer and triple-negative breast cancer.

Species: Human

FGFR  
Gastric Cancer   Triple-Negative Breast Cancer  
/
HY-126393 Carboxymethyl-β-cyclodextrin
Carboxymethyl-β-cyclodextrin is a cationic cyclodextrin used as a carrier for drugs. It has been shown to bind nonsteroidal anti-inflammatory drugs (NSAIDs) with high affinity and selectivity.
Biochemical Assay Reagents  
/
HY-P99453 Azintuxizumab
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin.

Species: Human

ADC Antibodies  
Cancer  
/
HY-158220A Hyaluronic acid Methacryloyl (MW 150 kDa)
Hyaluronic acid Methacryloyl (HAMA) MW 150 kDa is methacrylated hyaluronic acid that is biocompatible. Hyaluronic acid Methacryloyl is also used as a 3D printing hydrogel ink, which has the characteristics of fast photosensitive response, fast gelation speed and stable hydrogel performance. Hyaluronic acid Methacryloyl can quickly induce gelation with lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) under UV irradiation. The combination of Hyaluronic acid Methacryloyl and tissue-specific extracellular matrix (ECM) materials (such as pancreatic extracellular matrix (pECM)) will become an important source material for organoid culture.
Biochemical Assay Reagents  
/
HY-P99718 Lupartumab
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 (HY-P99719).

Species: Human

ADC Antibodies  
Cancer  
/
HY-P99788 Praluzatamab
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers.

Species: Human

ADC Antibodies   ALCAM/CD166  
Cancer  
/
HY-124081 N-Oleoyl-L-serine
N-Oleoyl-L-Serine is an endogenous amide of long-chain fatty acids with ethanolamine (N-acyl amides). N-Oleoyl-L-Serine is a lipid regulator of bone remodeling and stimulates osteoclast apoptosis. N-Oleoyl-L-Serine can be used for antiosteoporotic drug discovery development.
Apoptosis  
Metabolic or Endocrine Disease  
/
HY-158220 Hyaluronic acid Methacryloyl (MW 400 kDa)
Hyaluronic acid Methacryloyl (MW 400 kDa) (HAMA (MW 400 kDa)) is a methacrylated hyaluronic acid with biocompatibility. Hyaluronic acid Methacryloyl (MW 400 kDa) also serves as a 3D printing hydrogel ink, featuring rapid photoresponsiveness, fast gelation speed and stable hydrogel performance. Hyaluronic acid Methacryloyl (MW 400 kDa) can rapidly initiate gelation with lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) under ultraviolet irradiation. Moreover, the combination of Hyaluronic acid Methacryloyl with tissue-specific extracellular matrix (ECM) materials (such as pancreatic extracellular matrix (pECM)) acts as an important source material for organoid culture.
Biochemical Assay Reagents  
/
HY-113003 H-γ-Glu-Gln-OH
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy.
Others  
Cancer  
/
HY-P4192 Fomc-Gly-Gly-Phe-Gly-OH
Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit.
ADC Linkers  
Cancer  
/
HY-D0860 Tricine
Tricine is widely used as a buffer in protein electrophoresis, nucleic acid analysis, and immunology, which can help adjust pH and stabilize chemical reactions. In addition, the compound can also be used in research in certain medical fields, such as in antibody detection and drug screening.
Biochemical Assay Reagents  
/
HY-W009310 9-cis-Retinal
9-cis-Retinal is a natural retinoid. Dietary 9-cis-β-carotene generates 9-cis-retinoids via cleavage into 9-cis-retinal. 9-cis Retinal binds to cellular retinol-binding protein-I (CRBP-I) and CRBP-II with Kds of 8 nM and 5 nM, respectively. 9-cis-Retinal expedites differentiation and maturation of rod photoreceptors in retinal organoids.
Endogenous Metabolite   Organoid  
/
HY-P703935 GDF-15 Protein, Mouse (His)
The GDF-15 protein regulates food intake, energy balance, and body weight by binding to its receptor GFRAL. This activates GFRAL-expressing neurons in the brainstem, triggering "emergency circuits" in the central parabrachial nucleus and amygdala during stress. GDF-15 Protein, Mouse (His) is the recombinant mouse-derived GDF-15 protein, expressed by E. coli, with N-His labeled tag.

Species: Mouse; Source: E. coli

Cytokines and Growth Factors TGF-beta Superfamily Neurotrophic Factors Growth Differentiation Factor GDNF family Growth Differentiation Factor 15 (GDF-15)

/
HY-P704628 GDF-15 Protein, Human (His)
The GDF-15 protein is critical for regulating food intake, energy expenditure, and body weight in response to metabolic and toxin-induced stress. It binds to its receptor GFRAL and activates GFRAL-expressing neurons in the brainstem. GDF-15 Protein, Human (His) is the recombinant human-derived GDF-15 protein, expressed by E. coli, with N-His labeled tag.

Species: Human; Source: E. coli

Cytokines and Growth Factors TGF-beta Superfamily Neurotrophic Factors Growth Differentiation Factor GDNF family Growth Differentiation Factor 15 (GDF-15)

/
HY-P80777A p38 alpha/MAPK14 Antibody (YA252)(PBS only)
p38 alpha/MAPK14 Antibody (YA252) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 alpha/MAPK14.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85712 p38 alpha/MAPK14 Antibody (YA5404)
p38 alpha/MAPK14 Antibody (YA5404) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p38 alpha/MAPK14.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P86460 p38 alpha/MAPK14 Antibody (YA6152)
p38 alpha/MAPK14 Antibody (YA6152) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 alpha/MAPK14.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P89418 p38 MAPK Antibody (YA8861)
p38 MAPK Antibody (YA8861) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 MAPK. p38 MAPK Antibody detects endogenous levels of total p38α, p38β, p38γ and p38δ MAPK protein.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P810544 Phospho-p38 (Thr180) Antibody (YA9813)
Phospho-p38 (Thr180) Antibody (YA9813) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-p38 (Thr180).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-K6003 Basement Membrane Matrix GFR (Phenol Red)

MCE Growth Factor Reduced Basement Membrane Matrix (with Phenol Red) is primarily composed of natural basement membrane matrix extracted from mouse tumors and contains abundant extracellular matrix components and a variety of naturally occurring growth factors. This product is primarily designed for 3D organoid culture and other research applications requiring high-quality basement membrane matrix.

Cell Biology 3D Cell Culture Basement Membrane Matrix

/
HY-K6012 Tissue Dissociation Solution

MCE Tissue Dissociation Solution is able to gently and efficiently dissociate tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids.

Cell Biology 3D Cell Culture Organoid Research

/
HY-K6101 Human Breast Cancer Organoid Kit

MCE Human Breast Cancer Organoid Kit contains Breast Cancer Organoid Basal Medium A, Breast Cancer Organoid Supplement B (50×), Breast Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human breast cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6102 Human Lung Adenocarcinoma Organoid Kit

MCE Human Lung Adenocarcinoma Organoid Kit contains Lung Adenocarcinoma Organoid Basal Medium A, Lung Adenocarcinoma Organoid Supplement B (50×), Lung Adenocarcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human lung adenocarcinoma organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6106 Human Cholangiocarcinoma Organoid Kit

MCE Human Cholangiocarcinoma Organoid Kit contains Cholangiocarcinoma Organoid Basal Medium A, Cholangiocarcinoma Organoid Supplement B (50×), Cholangiocarcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human cholangiocarcinoma organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6112 Human Colonic Organoid Kit

MCE Human Colonic Organoid Kit contains Human Colonic Organoid Basal Medium A, Human Colonic Organoid Supplement B (50×), Human Colonic Organoid Supplement C (250×), and Human Colonic Organoid Supplement D (250×). This product can be used to efficiently construct human colonic organoid.

Cell Biology 3D Cell Culture Normal Tissue Organoid Culture Medium

/
HY-K6113 Human Intestinal Organoid Kit

MCE Human Intestinal Organoid Kit contains Intestinal Organoid Basal Medium A, Intestinal Organoid Supplement B (50×), Intestinal Organoid Supplement C (250×), and Intestinal Organoid Supplement D (250×). This product can be used to efficiently construct human intestinal organoid.

Cell Biology 3D Cell Culture Normal Tissue Organoid Culture Medium

/
HY-K6114 Human Gastric Epithelial Organoid Kit

MCE Human Gastric Epithelial Organoid Kit contains Gastric Epithelial Organoid Basal Medium A, Gastric Epithelial Organoid Supplement B (50×), Gastric Epithelial Organoid Supplement C (250×), and Gastric Epithelial Organoid Supplement D (250×). This product can be used to efficiently construct human gastric epithelial organoid.

Cell Biology 3D Cell Culture Normal Tissue Organoid Culture Medium

/
HY-K6115 Human Pancreatic Organoid Kit

MCE Human Pancreatic Organoid Kit contains Human Pancreatic Organoid Basal Medium A, Human Pancreatic Organoid Supplement B (50×), and Human Pancreatic Organoid Supplement C (250×).This product can be used to efficiently construct human pancreatic organoids.

Cell Biology 3D Cell Culture Normal Tissue Organoid Culture Medium

/
HY-K6119 Mouse Intestinal Organoid Kit

MCE Mouse Intestinal Organoid Kit contains Mouse Intestinal Organoid Basal Medium A, Mouse Intestinal Organoid Supplement B (50×), Mouse Intestinal Organoid Supplement C (250×) and EDTA. This product can be used to efficiently construct mouse intestinal organoid.

Cell Biology 3D Cell Culture Normal Tissue Organoid Culture Medium

/
HY-K6120 Mouse Colonic Organoid Kit

MCE Mouse Colonic Organoid Kit contains Colonic Organoid Basal Medium A, Colonic Organoid Supplement B (50×), Colonic Organoid Supplement C (250×), Colonic Organoid Supplement D (250×) and EDTA. This product can be used to efficiently construct mouse colonic organoid.

Cell Biology 3D Cell Culture Normal Tissue Organoid Culture Medium

/
HY-K6122 Human Bladder Cancer Organoid Kit

MCE Human Bladder Cancer Organoid Kit contains human bladder cancer organoid basal medium and culture supplement. This product can be used to efficiently construct Human Bladder Cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6137 Brain Glioma Organoid Kit

MCE Brain Glioma Organoid Kit contains brain glioma organoid basal medium and culture supplement. This product can be used to efficiently construct brain glioma organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6138 Rhabdomyosarcoma Organoid Kit

MCE Rhabdomyosarcoma Organoid Kit contains rhabdomyosarcoma organoid basal medium and culture supplement. This product can be used to efficiently construct rhabdomyosarcoma organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6139 Neuroblastoma Organoid Kit

MCE Neuroblastoma Organoid Kit contains Neuroblastoma organoid basal medium and culture supplement. This product can be used to efficiently construct Neuroblastoma organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6140 Hepatoblastoma Organoid Kit

MCE Hepatoblastoma Organoid Kit contains hepatoblastoma organoid basal medium and culture supplement. This product can be used to efficiently construct hepatoblastoma organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/

Keywords

organoid-based drug discovery | patient-derived organoids | tumor organoids | organoid biobank | drug screening | precision medicine | organoid-on-chip